Present and future treatment strategies for coronavirus disease 2019

被引:17
|
作者
Elekhnawy, Engy [1 ]
Kamar, Amal Abo [1 ]
Sonbol, Fatma [1 ]
机构
[1] Tanta Univ, Fac Pharm, Pharmaceut Microbiol, Tanta, El Gharbia Gove, Egypt
关键词
COVID-19; SARS-Cov-2; Cytokine storm; Respiratory distress syndrome; SEVERE COVID-19; ANAKINRA; TRIAL;
D O I
10.1186/s43094-021-00238-y
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background The recent pandemic of coronavirus disease 2019 (COVID-19) has resulted in many challenges to the healthcare organizations around the world. Unfortunately, until now, there are no proven effective therapeutic agents against this virus. Main body Several evolving studies suggest repurposing a potential list of drugs which have appropriate pharmacological and therapeutic effects to be used in treating COVID-19 cases. In the present review, we will summarize the potential drugs suggested to be repurposed to be utilized in the treatment of COVID-19 patients like lopinavir-ritonavir, ribavirin, baloxavir marboxil, favipiravir, remdesvir, umifenovir, chloroquine, hydroxychloroquine, azithromycin, corticosteroids, losartan, statins, interferons, nitric oxide, epoprostenol, tocilizumab, siltuximab, sarilumab anakinra, and ruxolitinib. In addition, we discussed the possible future therapeutic regimens based on the recent molecular and genomic discoveries. Conclusion This review could provide beneficial information about the potential current and future treatment strategies to treat the pandemic COVID-19 disease.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Neurological manifestations of coronavirus disease 2019: exploring past to understand present
    Ishita Desai
    Rajat Manchanda
    Niraj Kumar
    Ashutosh Tiwari
    Mritunjai Kumar
    Neurological Sciences, 2021, 42 : 773 - 785
  • [22] Coronavirus disease 2019: changing the future of emergency epistaxis management
    Devabalan, Y.
    Cereceda-Monteoliva, N.
    Lorenz, H.
    Magill, J. C.
    Unadkat, S.
    Ferguson, M.
    Rennie, C.
    JOURNAL OF LARYNGOLOGY AND OTOLOGY, 2021, 135 (08): : 675 - 679
  • [23] Implications of current and future approaches to coronavirus disease 2019 testing
    Smith, Rasheid
    Geary, Sean M.
    Salem, Aliasger K.
    FUTURE VIROLOGY, 2020, 15 (09) : 551 - 556
  • [24] Successful treatment of coronavirus disease 2019 in a patient with asthma
    Joshi, Avni Y.
    Mullakary, Roshini M.
    Iyer, Vivek N.
    ALLERGY AND ASTHMA PROCEEDINGS, 2020, 41 (04) : 296 - 300
  • [25] Tocilizumab: Trick or Treat in the Treatment of Coronavirus Disease 2019?
    Kumar, T.
    Hart, S.
    Sutter, J. B.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [26] Gender differences in treatment of Coronavirus Disease-2019
    Ambrosino, Immacolata
    Barbagelata, Elena
    Corbi, Graziamaria
    Ciarambino, Tiziana
    Politi, Cecilia
    Moretti, Anna Maria
    MONALDI ARCHIVES FOR CHEST DISEASE, 2020, 90 (04) : 646 - 656
  • [27] Treatment of coronavirus disease 2019 with saikatsugekito: A case series
    Irie, Yasuhito
    Nakae, Hajime
    Fukui, Shin
    TRADITIONAL & KAMPO MEDICINE, 2021, 8 (03) : 211 - 220
  • [28] Overview of coronavirus disease 2019: Treatment updates and advances
    Luo, Yung-Hung
    Chiu, Hwa-Yen
    Weng, Chia-Sui
    Chen, Yuh-Min
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2020, 83 (09) : 805 - 808
  • [29] Coronavirus disease 2019 vaccination and infertility treatment outcomes
    Avraham, Sarit
    Kedem, Alon
    Zur, Hilli
    Youngster, Michal
    Yaakov, Odelia
    Yerushalmi, Gil M.
    Gat, Itai
    Gidoni, Yariv
    Hochberg, Alyssa
    Baum, Micha
    Hourvitz, Ariel
    Maman, Ettie
    FERTILITY AND STERILITY, 2022, 117 (06) : 1291 - 1299
  • [30] Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019
    Barlow, Ashley
    Landolf, Kaitlin M.
    Barlow, Brooke
    Yeung, Siu Yan Amy
    Heavner, Jason J.
    Claassen, Cassidy W.
    Heavner, Mojdeh S.
    PHARMACOTHERAPY, 2020, 40 (05): : 416 - 437